Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04387773 · ClinicalTrials.gov registry record · Phase 4
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
A Phase 4 study of Parkinson Disease, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT04387773: Completed Phase 4 study of Parkinson Disease, sponsored by Oregon Health and Science University.
NCT04387773 is a Phase 4 study of Parkinson Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 8 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04387773, a Phase 4 study of Parkinson Disease, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using body-worn sensors.
Primary Outcome
Aim I: Investigate the effect of GOCOVRI™ on activity levels in people with Parkinson's disease (PD) and Levodopa induced dyskinesia (LID). Hypothesis I: We hypothesized that GOCOVRI™ would result in an increase of daily activity due to improvement in LID symptoms. Measure: number of walking bouts per hour
Conditions Studied
Interventions
- DRUG GOCOVRI
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
What the finished NCT04387773 record still lists
NCT04387773 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which GOCOVRI is the first listed.
NCT04387773 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04387773 about?
NCT04387773 is a clinical study titled "Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease". The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using body-worn sensors.
What is the current status of trial NCT04387773?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2020-11-05. Estimated completion is 2022-09-30.
What conditions does trial NCT04387773 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04387773?
The interventions under investigation include: GOCOVRI (DRUG).
Who is sponsoring clinical trial NCT04387773?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04387773 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04387773's enrollment target sits among peer trials
8 289th of 297 higher than 8 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
RECRUITING · Phase 4
-
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
RECRUITING · Phase 4
-
Personalized Real-Time DBS and PD Mechanisms
RECRUITING · Phase 4
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI